Mehran Sugar Mills Limited (MRNS)
Feb 11, 2025 - MRNS was delisted (reason: acquired by Immedica)
0.5500
+0.0010 (0.09%)
Inactive · Last trade price on Feb 11, 2025
Marinus Pharmaceuticals Revenue
Marinus Pharmaceuticals had revenue of 4.13B PKR in the quarter ending June 30, 2025, a decrease of -3.32%. This brings the company's revenue in the last twelve months to 13.95B, up 13.80% year-over-year. In the fiscal year ending September 30, 2024, Marinus Pharmaceuticals had annual revenue of 10.99B with 0.05% growth.
Revenue (ttm)
13.95B PKR
Revenue Growth
+13.80%
P/S Ratio
0.38
Revenue / Employee
50,183,723 PKR
Employees
278
Market Cap
18.74M USD
Revenue Chart
* This company reports financials in PKR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 10.99B | 5.34M | 0.05% |
| Sep 30, 2023 | 10.98B | 4.09B | 59.23% |
| Sep 30, 2022 | 6.90B | 834.49M | 13.76% |
| Sep 30, 2021 | 6.06B | -361.14M | -5.62% |
| Sep 30, 2020 | 6.42B | 1.11B | 20.95% |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionMRNS News
- 10 months ago - MARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc. - MRNS - Business Wire
- 11 months ago - Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc. - Business Wire
- 1 year ago - Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results - Business Wire
- 1 year ago - Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives - Business Wire
- 1 year ago - Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting - Business Wire
- 1 year ago - 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity - Benzinga
- 1 year ago - Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens - Business Wire
- 1 year ago - Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting - Business Wire